Across our campus and throughout our nearly 400 years, Harvard innovation—in medicine, technology, education, and beyond—has ...

From cancer immunotherapy to diabetes and weight loss breakthroughs, 2025’s top-selling drugs highlight how pharmaceutical ...

Psychiatric medication is controversial. While most recognise that mental health problems are caused by a tangle of psychological, social and biological factors, debates about solutions are polarised ...

AbbVie and IGI Therapeutics SA, a wholly owned subsidiary of New York-based Ichnos Glenmark Innovation, Inc. (IGI), have ...

AbbVie has entered into a $1 billion licensing agreement with IGI Therapeutics SA, for IGI's lead investigational drug for ...

The AI in Life Science Market is anticipated to experience a remarkable compound annual growth rate (CAGR) of around 25% in ...

A Financial District-based drug discovery company inked a $1 billion licensing agreement with pharmaceutical giant AbbVie to ...

Glenmark Pharmaceuticals has signed a groundbreaking deal with AbbVie to commercialize its underdevelopment drug, ISB 2001, ...

Weight-loss drugs have surged in popularity, promising rapid results with regular injections. Now, researchers from Japan report a way ...

San Diego-based Capstan is developing a potential first-in-class therapy to treat certain autoimmune disease by changing ...